Article body
It is estimated that 170 million people globally are infected with the hepatitis C virus (HCV). Chronic HCV infection can result in the development of liver cirrhosis and hepatocellular carcinoma, and therefore represents a substantial public health problem. Current drugs against HCV have poor safety profiles and limited effectiveness, especially against HCV genotype 1. As a result, there is considerable interest in identifying specific inhibitors of HCV replication that could be used either as an adjunct to current therapy or in place of it. This poster summarizes the replicative cycle of HCV and the principal targets for specific antiviral agents that are currently being developed. The poster is freely available thanks to support from Boehringer Ingelheim.
